Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights · Newly filed patent application to protect use of POLB 001 for new oncology indication · Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]
In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023. According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery. Check out the Evaluate team’s thoughts on the […]
Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg’s Scientific Advisory Board to guide clinical development of technology Licence expands Poolbeg’s existing exclusive licence to AnaBio’s oral vaccine delivery technology Investor Meet Company presentation on 14 December 2022 at 5:30pm Read more…
12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the […]
As part of its ‘Pharma Outlook for 2022’, leading healthcare publication, In Vivo, explored the outlook for US and EU venture capital funding in biopharma. Asking whether the sector can keep the momentum going for investments, it drew on the experience and insight of prominent investors [many among them our clients,] to provide comment on […]
